NASDAQ:GERN Geron (GERN) Stock Price, News & Analysis → 😱 This phenomenon is smashing regular market gains (From MillPub) (Ad) Free GERN Stock Alerts $4.08 +0.15 (+3.82%) (As of 05:27 PM ET) Add Compare Share Share Today's Range$3.88▼$4.2150-Day Range$1.75▼$4.1452-Week Range$1.64▼$4.30Volume16.90 million shsAverage Volume11.35 million shsMarket Capitalization$2.23 billionP/E RatioN/ADividend YieldN/APrice Target$6.10 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Geron alerts: Email Address Geron MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside47.3% Upside$6.10 Price TargetShort InterestBearish9.04% of Shares Sold ShortDividend StrengthN/ASustainability-2.80Upright™ Environmental ScoreNews Sentiment0.11Based on 18 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.34) to ($0.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.57 out of 5 starsMedical Sector264th out of 927 stocksBiotechnology Industry6th out of 28 stocks 4.4 Analyst's Opinion Consensus RatingGeron has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageGeron has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.04% of the outstanding shares of Geron have been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Geron has recently increased by 5.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGeron does not currently pay a dividend.Dividend GrowthGeron does not have a long track record of dividend growth. Previous Next 1.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGeron has received a -35.24% net impact score from Upright. The largest negative impact of Geron in category "GHG emissions" is driven by its "Nonwoven fabric machines" and "Textile spinning machines" products. See details.Environmental SustainabilityThe Environmental Impact score for Geron is -2.80. Previous Next 1.7 News and Social Media Coverage News SentimentGeron has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Geron this week, compared to 4 articles on an average week.Search InterestOnly 38 people have searched for GERN on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 20 people have added Geron to their MarketBeat watchlist in the last 30 days. This is a decrease of -31% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Geron insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Geron is held by insiders.Percentage Held by Institutions73.71% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Geron are expected to grow in the coming year, from ($0.34) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Geron is -12.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Geron is -12.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeron has a P/B Ratio of 9.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad MillPub😱 This phenomenon is smashing regular market gainsThanks to a little-known “Pathfinder” trading phenomenon… Traders have recently unlocked one of the most powerful idea-generation sources in the history of trading. At every single market open.Click here to save your seat and join the next LIVE workshop! About Geron Stock (NASDAQ:GERN)Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Read More GERN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GERN Stock News HeadlinesMay 1, 2024 | msn.comBaird Downgrades Geron (GERN)May 1, 2024 | americanbankingnews.comGeron (NASDAQ:GERN) Downgraded by Robert W. Baird to NeutralMay 1, 2024 | MillPub (Ad)😱 This phenomenon is smashing regular market gainsThanks to a little-known “Pathfinder” trading phenomenon… Traders have recently unlocked one of the most powerful idea-generation sources in the history of trading. At every single market open.April 30, 2024 | msn.comBaird downgrades Geron to neutral, cites valuation concernsApril 30, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Dyne Therapeutics (DYN) and Geron (GERN)April 30, 2024 | msn.comTD Cowen Initiates Coverage of Geron (GERN) with Buy RecommendationApril 30, 2024 | americanbankingnews.comGeron (NASDAQ:GERN) Receives New Coverage from Analysts at TD CowenApril 29, 2024 | msn.comTD Cowen starts Geron at buy, cites imetelstat market potentialMay 1, 2024 | MillPub (Ad)😱 This phenomenon is smashing regular market gainsThanks to a little-known “Pathfinder” trading phenomenon… Traders have recently unlocked one of the most powerful idea-generation sources in the history of trading. At every single market open.April 29, 2024 | benzinga.comNavigating 10 Analyst Ratings For GeronApril 25, 2024 | businesswire.comGeron to Announce First Quarter 2024 Financial Results on May 2, 2024April 24, 2024 | investorplace.com3 Red-Hot Biotech Rockets Blasting Off in 2024April 18, 2024 | businesswire.comGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2024 | seekingalpha.comConsidering The Merits Of A Gamble On Geron CorporationApril 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Geron Following Insightful Leadership Discussion and Promising Drug Development ProgressApril 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Carl Zeiss Meditec (GB:0DHC), Geron (GERN) and Zur Rose Group AG (Six Swiss: CH:DOCM)April 11, 2024 | finance.yahoo.comGeron Corporation (NASDAQ:GERN) Is Expected To Breakeven In The Near FutureApril 3, 2024 | businesswire.comGeron to Participate at Upcoming Investor Conferences in AprilMarch 27, 2024 | finance.yahoo.comGERN Mar 2024 3.500 putMarch 19, 2024 | markets.businessinsider.comGeron Announces Pricing Of $150 Mln Underwritten Offering Of Common Stock, Pre-Funded WarrantsMarch 19, 2024 | msn.comGeron announces pricing of $150M underwritten offeringMarch 19, 2024 | finance.yahoo.comGeron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsMarch 18, 2024 | finance.yahoo.comGERN240517C00003500 (GERN240517C00003500) Interactive Stock Chart - Yahoo FinanceMarch 18, 2024 | finance.yahoo.comGERN240517P00003500 (GERN240517P00003500) Interactive Stock Chart - Yahoo FinanceMarch 16, 2024 | finance.yahoo.comGERN Apr 2024 1.000 putMarch 16, 2024 | finance.yahoo.comGERN Apr 2024 1.500 callMarch 16, 2024 | wsj.comGeron Corp.See More Headlines Receive GERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/01/2024Next Earnings (Confirmed)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GERN CUSIP37416310 CIK886744 Webwww.geron.com Phone(650) 473-7700Fax650-473-7750Employees141Year FoundedN/APrice Target and Rating Average Stock Price Target$6.10 High Stock Price Target$10.00 Low Stock Price Target$4.50 Potential Upside/Downside+50.6%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,130,000.00 Net Margins-77,691.14% Pretax Margin-77,690.72% Return on Equity-63.33% Return on Assets-44.71% Debt Debt-to-Equity Ratio0.14 Current Ratio3.16 Quick Ratio3.16 Sales & Book Value Annual Sales$240,000.00 Price / Sales9,228.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book8.80Miscellaneous Outstanding Shares546,870,000Free Float530,468,000Market Cap$2.21 billion OptionableOptionable Beta0.62 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. John A. Scarlett M.D. (Age 73)Chairman of the Board, President & CEO Comp: $1.36MMs. Michelle J. Robertson (Age 57)Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer Comp: $340.98kDr. Andrew J. Grethlein Ph.D. (Age 60)Executive VP & COO Comp: $827.01kMr. Scott SamuelsExecutive VP, Chief Legal Officer & Corporate SecretaryMs. Aron FeingoldVice President of Investor Relations & Corporate CommunicationsMs. Shannon Odam (Age 49)Senior VP & Chief People Officer Ms. Melissa A. Kelly Behrs (Age 60)Executive VP of Business Operations & Chief Alliance Officer Comp: $753.22kMr. Anil Kapur (Age 54)Executive VP of Corporate Strategy & Chief Commercial Officer Comp: $654.89kMr. Edward E. Koval (Age 62)Executive VP & Chief Business Officer Dr. Faye Feller M.D. (Age 41)Executive VP & Chief Medical Officer More ExecutivesKey CompetitorsDynavax TechnologiesNASDAQ:DVAXChinook TherapeuticsNASDAQ:KDNYAmicus TherapeuticsNASDAQ:FOLDLigand PharmaceuticalsNASDAQ:LGNDIronwood PharmaceuticalsNASDAQ:IRWDView All CompetitorsInsiders & InstitutionsMirae Asset Global Investments Co. Ltd.Bought 18,667 shares on 5/1/2024Ownership: 0.016%Commonwealth Equity Services LLCBought 21,452 shares on 4/30/2024Ownership: 0.046%Private Advisor Group LLCSold 169,593 shares on 4/30/2024Ownership: 0.033%China Universal Asset Management Co. Ltd.Bought 42,109 shares on 4/29/2024Ownership: 0.019%Simplex Trading LLCBought 213,300 shares on 4/25/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions GERN Stock Analysis - Frequently Asked Questions Should I buy or sell Geron stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GERN shares. View GERN analyst ratings or view top-rated stocks. What is Geron's stock price target for 2024? 5 brokers have issued twelve-month price objectives for Geron's shares. Their GERN share price targets range from $4.50 to $10.00. On average, they predict the company's share price to reach $6.10 in the next year. This suggests a possible upside of 47.3% from the stock's current price. View analysts price targets for GERN or view top-rated stocks among Wall Street analysts. How have GERN shares performed in 2024? Geron's stock was trading at $2.11 at the start of the year. Since then, GERN stock has increased by 96.2% and is now trading at $4.14. View the best growth stocks for 2024 here. Are investors shorting Geron? Geron saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 49,420,000 shares, an increase of 5.9% from the March 31st total of 46,660,000 shares. Based on an average trading volume of 12,430,000 shares, the days-to-cover ratio is presently 4.0 days. View Geron's Short Interest. When is Geron's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our GERN earnings forecast. How can I listen to Geron's earnings call? Geron will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Geron's earnings last quarter? Geron Co. (NASDAQ:GERN) released its quarterly earnings data on Wednesday, February, 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. The biopharmaceutical company earned $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. Geron had a negative trailing twelve-month return on equity of 63.33% and a negative net margin of 77,691.14%. The firm's revenue for the quarter was down 77.7% compared to the same quarter last year. During the same period last year, the firm posted ($0.10) earnings per share. What ETFs hold Geron's stock? ETFs with the largest weight of Geron (NASDAQ:GERN) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), iShares Genomics Immunology and Healthcare ETF (IDNA), WisdomTree BioRevolution Fund (WDNA), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and SPDR S&P Biotech ETF (XBI). What is John A. Scarlett's approval rating as Geron's CEO? 5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees. What other stocks do shareholders of Geron own? Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), Organigram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO). Who are Geron's major shareholders? Geron's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (4.98%), Allspring Global Investments Holdings LLC (0.06%), Commonwealth Equity Services LLC (0.05%), Simplex Trading LLC (0.00%), Private Advisor Group LLC (0.03%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Andrew J Grethlein, Elizabeth G O'farrell, John A Scarlett, Olivia Kyusuk Bloom, Susan Molineaux and V Bryan Lawlis. View institutional ownership trends. How do I buy shares of Geron? Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GERN) was last updated on 5/1/2024 by MarketBeat.com Staff From Our Partners😱 This phenomenon is smashing regular market gainsMillPubHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceYour bank is lying to you.MyBankTrackerThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget Nvidia. This is the future of AIPorter & CompanyBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
